LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Enters Development Agreement With Astex Pharmaceuticals
18 mai 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
14 mai 2021 09h15 HE | Recro Pharma, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and...
logo.png
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
13 mai 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Proposed Public Offering of Common Stock
11 mai 2021 16h30 HE | Recro Pharma, Inc.
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
logo.png
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
11 mai 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
RevolutionLogo.png
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
03 mai 2021 07h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
researchdrivelogo.jpg
Global Antiviral Therapies Market Expected to Surpass to $66,016.5 Million and Exhibit a CAGR of 3.1% from 2020 to 2027 - Exclusive Report [Pages - 208] by Research Dive
12 avr. 2021 09h15 HE | Research Dive
New York, USA , April 12, 2021 (GLOBE NEWSWIRE) -- Research Dive in its latest published report estimates that the global antiviral therapies market will generate $66,016.5 million and exhibit...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Inducement Grants for New Staff
06 avr. 2021 07h00 HE | Recro Pharma, Inc.
MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
05 avr. 2021 07h00 HE | Recro Pharma, Inc.
Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing Significant Traction Already Achieved in First Months of 2021 MALVERN, Pa., April 05, 2021 ...
logo.jpg
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
22 mars 2021 09h15 HE | Processa Pharmaceuticals, Inc.
HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...